The partners will work together on a US commercialization strategy for Genetic Technologies' line of existing and future polygenic risk tests.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
Crowdfunding will help move the targeted sequencing-based test through the development process in hopes of commercializing it.
